

(4-Acetamidocyclohexyl) nitrate

Catalog No: tcsc0018447

 \checkmark Available SizesSize: 1mgSize: 5mgSize: 10mg \checkmark SpecificationsCAS No:
137213-91-3Formula:
 $C_8H_{14}N_2O_4$

Pathway: GPCR/G Protein

Target: Guanylate Cyclase

Purity / Grade:

Solubility:

10 mM in DMSO

Alternative Names: BM121307

Observed Molecular Weight:

202.21


Product Description

Copyright 2021 Taiclone Biotech Corp.



BM121307 is a **guanylate cyclase** activator that was in phase I development for the treatment of ischaemic heart disorders. The research has been discontinued.

In Vivo: The elimination of BM121307 and its metabolites via urine and feces amount to 76.5% after oral application, and to 80.7% of the applied dose after intravenous application. The major amount of radioactivity is eliminated via urine (69.4% and 73.6% of the dose, respectively), whereas the fecal elimination is found to be negligible. Investigations of the urinary samples show that the drug is metabolized to a high percentage trans-N-(4-Hydroxycyclohexyl) acetamide is the main metabolite; 73% of the radioactive compounds (after p.o.-administration and 69% after intravenous application could be identified as the alcohol of BM121307; the amounts of the drug totaled 9% and 13%, respectively^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.